[Chinese consensus on the use of antiarrhythmic drugs for rhythm control in atrial fibrillation]

Zhonghua Nei Ke Za Zhi. 2023 Apr 1;62(4):343-355. doi: 10.3760/cma.j.cn112138-20220402-00241.
[Article in Chinese]

Abstract

Rhythm control is crucial part of comprehensive management of atrial fibrillation (AF). Rhythm control can reduce the burden of AF effectively, reduce symptoms, and improve the prognosis in early AF. Antiarrhythmic drugs (AADs) are the first-line treatment for rhythm-control strategies. This consensus focuses on the principle of rhythm control in AF, the characteristics of AADs, and the medication recommendations for patients in different populations suffering from AF. Hence, this consensus aims to support clinical decision-making for AF therapy.

节律控制是心房颤动综合管理的重要部分,能有效降低房颤负荷、减轻患者症状,在早期房颤中有改善预后的证据。抗心律失常药物(AADs)是节律控制策略的一线推荐。本共识主要内容为房颤节律控制的整体原则、AADs的特性及不同人群房颤患者的用药建议,以供临床决策参考,指导合理规范用药。.

Publication types

  • English Abstract

MeSH terms

  • Anti-Arrhythmia Agents* / therapeutic use
  • Atrial Fibrillation* / drug therapy
  • China
  • Consensus
  • Humans

Substances

  • Anti-Arrhythmia Agents